In the Boardroom - Respiratory and Pulmonary

Filter

Current filters:

Respiratory and Pulmonary

Popular Filters

360 to 384 of 430 results

Aeras and CNBG in TB vaccine pact

18-01-2012

The global fight against the tuberculosis epidemic has received a boost as USA-based Aeras and the China…

AeresBiotechnologyChina National BiotecPharmaceuticalResearchRespiratory and PulmonaryVaccines

Valeant ups its bid for ISTA Pharma

17-01-2012

California, USA-based ophthalmology and allergy drug company ISTA Pharmaceuticals (Nasdaq: ISTA) says…

ISTA PharmaceuticalMergers & AcquisitionsOphthalmicsPharmaceuticalRespiratory and PulmonaryValeant Pharmaceuticals

GSK and Theravance to file COPD/asthma drug

10-01-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) and partner USA-based Theravance (Nasdaq: THRX), in which…

GlaxoSmithKlinePharmaceuticalRegulationRelovairResearchRespiratory and PulmonaryTheravance

Johnson & Johnson stops Doribax trial; reportedly agrees Risperdal settlement

09-01-2012

The US Food and Drug Administration says that a recent clinical trial with Doribax (doripenem) being…

DoribaxFinancialJanssenJohnson & JohnsonLegalNeurologicalNorth AmericaPharmaceuticalResearchRespiratory and PulmonaryRisperdal

Takeda ends Daxas co-promotion with MSD; Actos law suits

03-01-2012

Japan’s largest drugmaker, Takeda Pharmaceuticals (TYO: 4502) says that it has reached a mutual…

ActosDaxasDiabetesLegalLicensingMerck & CoNycomedPharmaceuticalRespiratory and PulmonaryTakeda Pharmaceuticals

AstraZeneca takes option on Prosidion diabetes assets; advances asthma drug

22-12-2011

Looking to expand its R&D pipeline in the face of several recent product failures and facing a “patent…

DiabetesDynavax TechnologiesLicensingPharmaceuticalProsidionResearchRespiratory and Pulmonary

COPD market to grow to more than $13.4 billion in 2020

19-12-2011

As a result of an expanding aging population, increases in drug treatment and the uptake of premium priced…

Boehringer IngelheimGlobalMarkets & MarketingolodaterolPharmaceuticalRespiratory and Pulmonarytiotropium

Germany’s IQWIG negative on InterMune’s Esbriet

18-12-2011

US biotech firm InterMune (Nasdaq: ITMN) says that Germany’s private Institute for Quality and Efficiency…

BiotechnologyEsbrietEuropeInterMuneRare diseasesRegulationRespiratory and Pulmonary

NICE wants more data on Daxas

08-12-2011

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has today issued final…

DaxasEuropeMerck & CoPharmaceuticalPricingRegulationRespiratory and Pulmonary

Theratechnologies to quit COPD program

08-12-2011

Canada-based Theratechnologies (TSX: TH.TO) revealed yesterday that it is discontinuing its muscle wasting…

EgriftaFinancialNephrology and HepatologyPharmaceuticalResearchRespiratory and PulmonarytesamorelinTheratechnologies

MedicinesCo takes equity stake in GeNO, gaining access to nitric oxide platforms

06-12-2011

USA-based The Medicines Company (Nasdaq: MDCO) says it has acquired a non-controlling equity investment…

GeNOLicensingMergers & AcquisitionsPharmaceuticalRespiratory and PulmonaryThe Medicines Company

South Africa debuts new five-year HIV and tuberculosis plan

05-12-2011

Coinciding with Worlds AIDS day last week, the South African government launched its new national strategic…

Anti-viralsHealthcarePharmaceuticalRespiratory and PulmonaryRest of the World

Paladin gets certain rights to Immuron’s Travelan in up to C$117 million deal

30-11-2011

Melbourne, Australia-based Immuron (ASX: IMC) and Canada’s Paladin Labs (TSX: PLB) have signed a…

Gastro-intestinalsImmuronLicensingPaladin LabsPharmaceuticalRespiratory and PulmonaryTravelan

New global data on influenza vaccine provision and level of support for immunization policies

28-11-2011

The findings of two studies being published this week in peer-reviewed journals look at global vaccination…

GlobalHealthcarePharmaceuticalRespiratory and PulmonaryVaccines

Novartis and Vectura COPD drug candidate NVA237 filed for approval in Japan

28-11-2011

The Japanese subsidiary of Swiss drug major Novartis (NOVO: VX) has filed an application for sales and…

Asia-PacificFinancialNovartisPharmaceuticalRegulationRespiratory and PulmonarySeebriVectura

Adeona Pharma and Intrexon collaborate for synthetic DNA-based PAH therapy

22-11-2011

USA-based Adeona Pharmaceuticals (NYSE Amex: AEN) and the Human Therapeutics Division of Intrexon Corp…

Adeona PharmaCardio-vascularIntrexonLicensingPharmaceuticalResearchRespiratory and Pulmonary

Eisai in deal with Novartis to co-promote COPD drugs in Japan

21-11-2011

Japanese drugmaker Eisai (TYO: 4523) has entered into a Japan co-promotion agreement with the local subsidiary…

Asia-PacificEisaiLicensingMarkets & MarketingNovartisOnbrezPharmaceuticalRespiratory and Pulmonary

Almirall starts Ph III COPD trial; collaborates with BioFocus; and posts sales and earnings downturn

16-11-2011

There was a batch of news from Spain’s largest drugmaker Almirall (ALM. MC), starting with the announcement…

aclidiniumAlmirallFinancialForest LaboratoriesFormoterol Fumarate Inhalation PowderPharmaceuticalResearchRespiratory and Pulmonary

Faes Farma licences bilastine´s marketing rights in Indonesia to Kalbe

14-11-2011

Spanish drugmaker Faes Farma has signed a licence agreement for the commercialization of its antihistamine…

Asia-PacificbilastineFaes FarmaKalbe PharmaLicensingPharmaceuticalRespiratory and Pulmonary

Skyepharma updates on Exparel, Flutiform and financial position

14-11-2011

UK drug developer SkyePharma (LSE: SKP) yesterday issued an update on its R&D pipeline and provided an…

Anti-Arthritics/RheumaticsExparelFinancialFlutiformLodotraPharmaceuticalRegulationResearchRespiratory and PulmonarySkyepharma

Mylan to acquire Pfizer generic respiratory delivery platform; challenge to GSK

10-11-2011

US generic drug major Mylan (Nasdaq: MYL) has entered into an agreement with global pharma behemoth Pfizer…

Advair DiskusGenericsGlaxoSmithKlineLicensingMylan LaboratoriesPfizerPharmaceuticalRespiratory and PulmonarySeretide

Vertex’ Kalydeco marks a milestone in fight against cystic fibrosis

06-11-2011

The oral drug ivacaftor (VX-770) provides major, sustained improvement in lung function, growth and other…

ivacaftorKalydecoPharmaceuticalRare diseasesResearchRespiratory and PulmonaryVertex

Anti-inflammatory therapeutics market to grow to $85.9 billion in 2017

06-11-2011

The anti-inflammatory therapeutics market accounted for $32.3 billion in 2002 from its seven major indications.…

Anti-Arthritics/RheumaticsGastro-intestinalsMarkets & MarketingNeurologicalPharmaceuticalRespiratory and Pulmonary

Vectura shares fall as partner Novartis reports US delay for lung cancer drug

26-10-2011

Shares of UK-based Vectura (LSE: VEC) tumbled 22% at 66 pence on Tuesday, after the company revealed…

NovartisPharmaceuticalRegulationResearchRespiratory and PulmonarySeebriVectura

360 to 384 of 430 results

Back to top